Literature DB >> 12878476

Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors.

Martin Ulrich Braun1, Daria Mochly-Rosen.   

Abstract

Neonatal primary cardiac fibroblasts in defined medium continue to proliferate. Here, we show that phorbol ester inhibited and transforming growth factor-beta1 (TGFbeta1) stimulated this fibroblast proliferation. Cardiac fibroblasts contain six protein kinase C (PKC) isozymes: alpha-, delta-, epsilon-, betaI-, betaII-, and zeta-PKC. To evaluate the effect of different PKC isozymes on the proliferation of these cells, we used isozyme-selective PKC inhibitors. Inhibition of endogenous delta-PKC with deltaV1-1, an isozyme-selective translocation inhibitor, resulted in increased basal thymidine incorporation by 58 +/- 12% of control cells, but did not affect TGFbeta1-induced cell growth. Inhibition of endogenous zeta-PKC in neonatal rat cardiac fibroblasts with zeta-pseudosubstrate, a selective inhibitor for the atypical PKC isozymes, revealed an opposite effect; this inhibitor reduced basal growth to 45 +/- 11% and TGFbeta1-induced growth to 61 +/- 10%. Other isozyme-specific inhibitors used in this study did not alter basal or TGFbeta1-stimulated fibroblast growth. Taken together, our data provide evidence that delta-PKC inhibits and zeta-PKC stimulates proliferation of neonatal rat cardiac fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878476     DOI: 10.1016/s0022-2828(03)00142-1

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  21 in total

1.  The many hats of protein kinase Cδ: one enzyme with many functions.

Authors:  Nir Qvit; Daria Mochly-Rosen
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

2.  Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide.

Authors:  Tamar Liron; Leon E Chen; Hanita Khaner; Alice Vallentin; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2007-01-24       Impact factor: 5.000

3.  Nociceptor beta II, delta, and epsilon isoforms of PKC differentially mediate paclitaxel-induced spontaneous and evoked pain.

Authors:  Ying He; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

Review 4.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

5.  Highly Specific Modulators of Protein Kinase C Localization: Applications to Heart Failure.

Authors:  Nir Qvit; Daria Mochly-Rosen
Journal:  Drug Discov Today Dis Mech       Date:  2010

6.  Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras.

Authors:  T Zhu; T Tsuji; C Chen
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

7.  Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure.

Authors:  Koichi Inagaki; Tomoyoshi Koyanagi; Natalia C Berry; Lihan Sun; Daria Mochly-Rosen
Journal:  Hypertension       Date:  2008-04-14       Impact factor: 10.190

8.  Protein kinase Cdelta negatively regulates hedgehog signaling by inhibition of Gli1 activity.

Authors:  Qingsong Cai; Jing Li; Tianyan Gao; Jingwu Xie; B Mark Evers
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

9.  Protein kinase Czeta attenuates hypoxia-induced proliferation of fibroblasts by regulating MAP kinase phosphatase-1 expression.

Authors:  Megan D Short; Stephanie M Fox; Ching F Lam; Kurt R Stenmark; Mita Das
Journal:  Mol Biol Cell       Date:  2006-02-08       Impact factor: 4.138

Review 10.  Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors:  Zhongwei Liu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.